DocSym
β
Searchsearch
Search
(N00.4) Acute nephritic syndrome : diffuse endocapillary proliferative glomerulonephritis
More details coming soon
327 610 in individuals diagnosis acute nephritic syndrome : diffuse endocapillary proliferative glomerulonephritis confirmed
11 926 deaths with diagnosis acute nephritic syndrome : diffuse endocapillary proliferative glomerulonephritis
4% mortality rate associated with the disease acute nephritic syndrome : diffuse endocapillary proliferative glomerulonephritis
Diagnosis acute nephritic syndrome : diffuse endocapillary proliferative glomerulonephritis is diagnosed Women are 6.85% more likely than Men
152 586
Men receive the diagnosis acute nephritic syndrome : diffuse endocapillary proliferative glomerulonephritis
4 246 (2.8 %)Died from this diagnosis.
100
95
90
85
80
75
70
65
60
55
50
45
40
35
30
25
20
15
10
5
0
175 024
Women receive the diagnosis acute nephritic syndrome : diffuse endocapillary proliferative glomerulonephritis
7 680 (4.4 %)Died from this diagnosis.
Risk Group for the Disease acute nephritic syndrome : diffuse endocapillary proliferative glomerulonephritis - Men and Women aged 5-9
In Men diagnosis is most often set at age 0-95+
in in men, the disease manifests at any agein in women, the disease manifests at any age
In Women diagnosis is most often set at age 0-95+
Disease Features acute nephritic syndrome : diffuse endocapillary proliferative glomerulonephritis
Absence or low individual and public risk
Acute nephritic syndrome : diffuse endocapillary proliferative glomerulonephritis - what does this mean
Acute nephritic syndrome is caused by diffuse endocapillary proliferative glomerulonephritis, which is an immune-mediated inflammatory process that affects the glomeruli in the kidneys. it is characterized by increased permeability of the glomerular capillaries, leading to proteinuria, edema, and hypertension.
What happens during the disease - acute nephritic syndrome : diffuse endocapillary proliferative glomerulonephritis
Acute nephritic syndrome is caused by a type of glomerulonephritis known as diffuse endocapillary proliferative glomerulonephritis. this is an autoimmune disorder in which the body's own immune system mistakenly attacks the glomeruli, the tiny filters in the kidneys that help remove waste and excess fluid from the blood. the inflammation caused by this attack leads to the leakage of proteins and red blood cells into the urine, resulting in the symptoms of acute nephritic syndrome.
Clinical Pattern
More details coming soon
How does a doctor diagnose
- Complete medical history and physical examination
- Urine analysis
- Complete blood count (CBC)
- Serum creatinine and blood urea nitrogen (BUN) levels
- Urinalysis
- Renal ultrasound
- Kidney biopsy
- Renal angiography
- Renal function tests
- Renal imaging studies
- Blood and urine culture
Treatment and Medical Assistance
Main Goal of Treatment:
Reduce inflammation and slow progression of the disease.
- Prescribe corticosteroids and immunosuppressants to reduce inflammation.
- Monitor kidney function regularly through blood and urine tests.
- Prescribe medications to lower blood pressure.
- Prescribe diuretics to reduce fluid retention.
- Prescribe antibiotics to prevent and treat infections.
- Prescribe iron supplements to treat anemia.
- Recommend lifestyle changes, such as reducing sodium intake and increasing physical activity.
- Refer patient to a dietitian to develop a healthy eating plan.
- Recommend regular follow-up appointments to monitor progress.
16 Days of Hospitalization Required
Average Time for Outpatient Care Not Established
Acute nephritic syndrome : diffuse endocapillary proliferative glomerulonephritis - Prevention
The best way to prevent acute nephritic syndrome (diffuse endocapillary proliferative glomerulonephritis) is to maintain a healthy lifestyle, including a balanced diet, regular exercise, and avoiding smoking and excessive alcohol consumption. additionally, it is important to maintain good hygiene and to get regular check-ups to detect any early signs of the disease.